Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

Significance Growing evidence suggests that successful intervention in many human cancers will require combinations of therapeutic agents. Critical to this effort will be a detailed understanding of the crosstalk between signaling networks that modulate proliferation, cell death, drug sensitivity, and acquired resistance. Here we investigated DNA-damage signaling elicited by small-molecule inhibitors against MAP/ERK kinase (MEK) and PI3K in melanoma cells. This work, performed using cutting-edge mass spectrometry proteomics, uncovered a burst of signaling among proteins in the DNA-damage pathway upon initiation of the cell-death program by agents targeting the RAS–RAF–MEK and PI3K–AKT–mTOR pathways. These signals may prove important to the short- and long-term sensitivity of tumor cells to MEK- and PI3K-targeted therapies. Targeted therapeutics that block signal transduction through the RAS–RAF–MEK and PI3K–AKT–mTOR pathways offer significant promise for the treatment of human malignancies. Dual inhibition of MAP/ERK kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) with the potent and selective small-molecule inhibitors GDC-0973 and GDC-0941 has been shown to trigger tumor cell death in preclinical models. Here we have used phosphomotif antibodies and mass spectrometry (MS) to investigate the effects of MEK/PI3K dual inhibition during the period immediately preceding cell death. Upon treatment, melanoma cell lines responded by dramatically increasing phosphorylation on proteins containing a canonical DNA damage-response (DDR) motif, as defined by a phosphorylated serine or threonine residue adjacent to glutamine, [s/t]Q. In total, >2,000 [s/t]Q phosphorylation sites on >850 proteins were identified by LC-MS/MS, including an extensive network of DDR proteins. Linear mixed-effects modeling revealed 101 proteins in which [s/t]Q phosphorylation was altered significantly in response to GDC-0973/GDC-0941. Among the most dramatic changes, we observed rapid and sustained phosphorylation of sites within the ABCDE cluster of DNA-dependent protein kinase. Preincubation of cells with the inhibitors of the DDR kinases DNA-dependent protein kinase or ataxia-telangiectasia mutated enhanced GDC-0973/GDC-0941–mediated cell death. Network analysis revealed specific enrichment of proteins involved in RNA metabolism along with canonical DDR proteins and suggested a prominent role for this pathway in the response to MEK/PI3K dual inhibition.

[1]  J. Downward Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.

[2]  J. Rush,et al.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.

[3]  M. Belvin,et al.  GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway , 2011, Molecular Cancer Therapeutics.

[4]  M. Lavin,et al.  ATM Activation by Oxidative Stress , 2010, Science.

[5]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[6]  S. T. Kim,et al.  Substrate Specificities and Identification of Putative Substrates of ATM Kinase Family Members* , 1999, The Journal of Biological Chemistry.

[7]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[8]  Matthias Mann,et al.  Unbiased RNA–protein interaction screen by quantitative proteomics , 2009, Proceedings of the National Academy of Sciences.

[9]  Gunther Schadow,et al.  Protein quantification in label-free LC-MS experiments. , 2009, Journal of proteome research.

[10]  S. Lees-Miller,et al.  DNA-PK: the means to justify the ends? , 2008, Advances in immunology.

[11]  David J. Chen,et al.  ATM-Dependent and -Independent Dynamics of the Nuclear Phosphoproteome After DNA Damage , 2010, Science Signaling.

[12]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[13]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[14]  Gary Box,et al.  The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer . , 2008, Journal of medicinal chemistry.

[15]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[16]  J. Blenis,et al.  SKAR Links Pre-mRNA Splicing to mTOR/S6K1-Mediated Enhanced Translation Efficiency of Spliced mRNAs , 2008, Cell.

[17]  Dexin Kong,et al.  Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. , 2009, Biological & pharmaceutical bulletin.

[18]  T. Misteli,et al.  Activation of the Cellular DNA Damage Response in the Absence of DNA Lesions , 2008, Science.

[19]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[20]  Ruedi Aebersold,et al.  Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs , 2012, BMC Bioinformatics.

[21]  Mark Merchant,et al.  Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. , 2012, Cancer research.

[22]  Wei Zhou,et al.  In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.

[23]  David J. Chen,et al.  DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. , 2006, DNA repair.

[24]  D. H. Larsen,et al.  Site-specific Phosphorylation Dynamics of the Nuclear Proteome during the DNA Damage Response* , 2010, Molecular & Cellular Proteomics.

[25]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[26]  R. de Cabo,et al.  AsSIRTing the DNA damage response. , 2008, Trends in cell biology.

[27]  B. A. Ballif,et al.  ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.

[28]  S. Burma,et al.  The Dual PI 3 K / mTOR Inhibitor NVP-BEZ 235 Is a Potent Inhibitor of ATM-and DNA-PKCs-Mediated DNA Damage Responses 1 , 2 , 2014 .

[29]  W. Sellers,et al.  Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.

[30]  S. Burma,et al.  The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. , 2012, Neoplasia.

[31]  K. Moelling,et al.  Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.

[32]  S. Gygi,et al.  Profiling of UV-induced ATM/ATR signaling pathways , 2007, Proceedings of the National Academy of Sciences.

[33]  Steven P Gygi,et al.  The impact of peptide abundance and dynamic range on stable-isotope-based quantitative proteomic analyses. , 2008, Journal of proteome research.

[34]  Steven P Gygi,et al.  Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases , 2010, Science Signaling.

[35]  S. Opiyo,et al.  Distinct roles for DNA-PK, ATM and ATR in RPA phosphorylation and checkpoint activation in response to replication stress , 2012, Nucleic acids research.

[36]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[37]  J. Sarkaria,et al.  Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. , 1998, Cancer research.

[38]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[39]  Katheryn Meek,et al.  Chapter 2 DNA-PK , 2008 .

[40]  I. Cristea,et al.  Functional Proteomics Establishes the Interaction of SIRT7 with Chromatin Remodeling Complexes and Expands Its Role in Regulation of RNA Polymerase I Transcription* , 2011, Molecular & Cellular Proteomics.

[41]  Steven P Gygi,et al.  A probability-based approach for high-throughput protein phosphorylation analysis and site localization , 2006, Nature Biotechnology.

[42]  J. Avruch,et al.  Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. , 2001, Physiological reviews.

[43]  B. Hemmings,et al.  PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. , 2008, Molecular cell.

[44]  J. Dodge,et al.  Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. , 1994, Cancer research.

[45]  Qi Ding,et al.  trans Autophosphorylation at DNA-Dependent Protein Kinase's Two Major Autophosphorylation Site Clusters Facilitates End Processing but Not End Joining , 2007, Molecular and Cellular Biology.

[46]  Timothy Woods,et al.  Autophosphorylation of the Catalytic Subunit of the DNA-Dependent Protein Kinase Is Required for Efficient End Processing during DNA Double-Strand Break Repair , 2003, Molecular and Cellular Biology.